Abstract
Intraocular tumours reside within an organ that provides sanctuary from many immunological defence mechanisms. Antigens displayed on many intraocular tumours can elicit an aberrant systemic immune response in which systemic antigen-specific delayed-type hypersensitivity (DTH) is actively downregulated, thus denying the host one potential effector mechanism for controlling its intraocular tumour. Constituents within the aqueous humour inhibit the expression of DTH and natural killer cell effector mechanisms within the eye and thus protect intraocular tumours from immune-mediated rejection. Some experimental intraocular tumours in mice express potent tumour-specific antigens that stimulate the expansion of tumour-specific robust cytotoxic T lymphocyte (CTL) populations which enter the eye and mediate tumour rejection by piecemeal tumour necrosis. However, the presence of tumour-infiltrating lymphocytes (TIL) within an intraocular tumour does not inevitably lead to tumour resolution. In some cases CTL precursors infiltrate the intraocular tumour but fail to differentiate into mature cytolytic effector cells. Although uveal melanomas express melanoma-specific and melanoma-associated antigens that are capable of eliciting both humoral and cellular immunity, formidable barriers prevent the expression of tumour immunity. These barriers include: (a) anterior chamber-associated immune deviation; (b) in situ suppression of DTH effector cells; (c) suppression of natural killer cell activity in oculi; and (d) inactivation of the complement cascade by regulatory proteins expressed on uveal melanoma cells.
Similar content being viewed by others
Article PDF
References
Streilein JW . Unravelling immune privilege. Science 1995;270:1158–9.
Niederkorn JY . Immune privilege and immune regulation in the eye. Adv Immunol 1990;48:191–226.
Greene HSN, Lund PK . The heterologous transplantation of human cancers. Cancer Res 1944;4:352–63.
Jiang LQ, Jorquera M, Streilein JW . Immunologic consequences of intraocular implantation of retinal pigment epithelial allografts. Exp Eye Res 1994;58:719–28.
Jiang LQ, Jorquera M, Streilein JW . Subretinal space and vitreous cavity as immunologically privileged sites for retinal allografts. Invest Ophthalmol Vis Sci 1993;34:3347–54.
Cochran AJ, Foulds WS, Damato BE, Trope GE, Morrison L, Lee WR . Assessment of immunological techniques in diagnosis of ocular malignant melanoma. Br J Ophthalmol 1985;69:171–6.
Goslings WRO, Blom DJR, de Waard-Siebinga I, van Beelen E, Claas FHJ, Jager MJ, Gorter A . Membrane-bound regulators of complement activation in uveal melanomas. Invest Ophthalmol Vis Sci 1996;37:1884–91.
Char DH, Hollinshead A, Cogan DG, Ballantine E, Hogan MJ, Herberman RB . Cutaneous delayed hypersensitivity reactions to soluble melanoma antigen in patients with ocular malignant melanoma. N Engl J Med 1974;291:274–7.
Kan-Mitchell J, Liggett PE, Harel W, Steinman L, Nitta T, Oksenberg JR, et al. Lymphocytes cytotoxic to uveal and skin melanoma cells from peripheral blood of ocular melanoma patients. Cancer Immunol Immunother 1991;33:333–40.
Huang XQ, Mitchell MS, Liggett PE, Murphree AL, Kan-Mitchell J . Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from choroidal melanoma patients. Cancer Immunol Immunother 1994;38:399–405.
Niederkorn JY, Streilein JW, Shadduck JA . Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice. Invest Ophthalmol Vis Sci 1981;20:355–63.
Niederkorn JY, Streilein JW . Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases. J Immunol 1982;128:2470–4.
Niederkorn JY, Streilein JW . Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T-lymphocyte and helper T-lymphocyte responses. J Immunol 1983;131:2670–4.
Streilein JW, Niederkorn JY . Induction of anterior chamber-associated immune deviation requires an intact functional spleen. J Exp Med 1981;153:1058–67.
Niederkorn JY . Suppressed cellular immunity in mice harboring intraocular melanomas. Invest Ophthalmol Vis Sci 1984;25:447–54.
Knisely TL, Niederkorn JY . Emergence of a dominant cytotoxic T lymphocyte (CTL) antitumor effector from tumor infiltrating cells in the anterior chamber of the eye. Cancer Immunol Immunother 1990;30:323–30.
Knisely TL, Luckenbach MW, Fischer BJ, Niederkorn JY . Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors. J Immunol 1987;138:4515–23.
Marchai G, Seman M, Milin G, Truffa-Bachi P, Zilberfard V . Local adoptive transfer of skin delayedtype hypersensitivity initiated by a single T lymphocyte. J Immunol 1982;129:954–8.
Benson JL, Niederkorn JY . In situ suppression of delayed-type hypersensitivity: another mechanism of sustaining the immune privilege of the anterior chamber. Immunology 1991;74:153–9.
Ma D, Alizadeh H, Comerford SA, Gething MJ, Sambrook JF, Anand R, Niederkorn JY . Rejection of intraocular tumors from transgenic mice by tumor-infiltrating lymphocytes. Curr Eye Res 1994;13:361–9.
Lang JR, Davidorf FH, Baba N . The prognostic significance of lymphocytic infiltration in malignant melanoma of the choroid. Cancer 1977;40:2388–94.
Durie FH, Campbell AM, Lee WR, Damato BE . Analysis of lymphocytic infiltration in uveal melanoma. Invest Ophthalmol Vis Sci 1990;31:2106–10.
Meecham WJ, Char DH, Kaleta-Michaels S . Infiltrating lymphocytes and antigen expression in uveal melanoma. Ophthalmic Res 1992;24:20–6.
Ksander BR, Rubsamen P, Olsen K, Cousins S, Streilein JW . Studies of tumor-infiltrating lymphocytes from a choroidal melanoma. Invest Ophthalmol Vis Sci 1991;32:3198–208.
Davidorf FH, Lang JR . Immunology and immunotherapy of malignant uveal melanomas. In: Peyman GA, Apple DJ, Sanders DR, editors. Intraocular tumors. New York: Appleton/Century/Crofts, 1977:119–33.
Kremer I, Gilad E, Kahan E, Derazne E, Bar-Ishak R . Necrosis and lymphocytic infiltration in choroidal melanomas. Acta Ophthalmol (Copenh) 1991;69:347–51.
Whelchel JC, Farah SE, McLean IW, Burnier MN . Immunochemistry of infiltrating lymphocytes in uveal melanoma. Invest Ophthalmol Vis Sci 1993;34:2603–6.
Nitta T, Oksenberg JR, Rao NA, Steinman L . Predominant expression of T cell receptor Vα7 in tumor-infiltrating lymphocytes of uveal melanoma. Science 1990;249:672–4.
Durie FH, George WD, Campbell AM, Damato BE . Analysis of clonality of tumour infiltrating lymphocytes in breast cancer and uveal melanoma. Immunol Lett 1992;33:263–70.
Ksander BR, Bando Y, Acevedo J, Streilein JW . Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors. Cancer Res 1991;51:3153–8.
Ksander BR, Mammolenti MM, Streilein JW . Termination of immune privilege in the anterior chamber of the eye when tumor-infiltrating lymphocytes acquire cytolytic function. Transplantation 1991;52:128–33.
Apte R, Niederkorn JY . Isolation and characterization of a unique natural killer cell inhibitory factor present in the anterior chamber of the eye. J Immunol 1996;156:2667–73.
Jampel HD, Roche N, Stark WJ, Roberts AB . Transforming growth factor-β in human aqueous humor. Curr Eye Res 1990;9:963–9.
Streilein JW, Cousins SW . Aqueous humor factors and their effect on the immune response in the anterior chamber. Curr Eye Res 1990;9:175–82.
Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, et al. Effects of transforming growth factor β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 1986;136:3916–20.
Ma D, Luyten GP, Luider TM, Niederkorn JY . Relationship between natural killer cell susceptibility and metastasis of human uveal melanoma cells in a murine model. Invest Ophthalmol Vis Sci 1995;36:435–41.
Tanihara H, Yoshida M, Matsumoto M, Yoshimura N . Identification of transforming growth factor-β expressed in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci 1993;34:413–9.
Connor TB Jr, Roberts AB, Sporn MB, Danielpour D, Dart LL, Michels RG et al. Correlation of fibrosis and transforming growth factor-β type 2 levels in the eye. J Clin Invest 1989;83:1661–6.
Streilein JW, Niederkorn JY . Induction of anterior chamber-associated immune deviation requires an intact functional spleen. J Exp Med 1981;153:1058–67.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Niederkorn, J. Immunoregulation of intraocular tumours. Eye 11, 249–254 (1997). https://doi.org/10.1038/eye.1997.60
Issue Date:
DOI: https://doi.org/10.1038/eye.1997.60